CORRECTION

Correction to: Detection efficacy of PET/CT with ^{18}F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study

Tomoaki Otani[1] · Tsuneo Saga[1] · Takayoshi Ishimori[1,2] · Eitaro Kidera[1] · Yoichi Shimizu[1] · Rihito Aizawa[3] · Kiyonao Nakamura[3] · Takayuki Goto[4] · Shusuke Akamatsu[4] · Takashi Mizowaki[3] · Yuji Nakamoto[1]

Correction to:
Annals of Nuclear Medicine (2022) 36:302–309
https://doi.org/10.1007/s12149-021-01704-6

The authors would like to correct the errors in the original article. The correction details are given below:

The contents of Tables 2, 4 were incorrect. The correct Tables 2 and 4 are given below.

The last sentence under the "Results", under the subheading "Patient-based analysis" in page 3 should be "When patients were divided into two groups according to GS, the detection rate in patients with GS of 8 and 9 tended to be higher than that in patients with GS of 6 and 7 [79% (33/42) vs. 60% (18/30)], although this difference was not statistically significant ($p = 0.087$).".

The p values were corrected in the subheading "Diagnostic performance according to initial treatment methods" under the "Results" section as given below:

The overall detection rate of recurrence tended to be higher in patients who received RT than those underwent RP (81% (30/37) vs. 60% (21/35), $p = 0.049$). In patients with PSA levels greater than 0.5 ng/ml, no significant difference in the detection rate was observed between patients who underwent RP and those who received RT (73% (19/26) vs. 81% (30/37), $p = 0.452$).

The second sentence under the heading "Conclusion" should be deleted.

✉ Yuji Nakamoto
ynakamo1@kuhp.kyoto-u.ac.jp

[1] Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-Ku, Kyoto 606-8507, Japan

[2] Department of Radiology, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

[3] Department of Radiation Oncology Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan

[4] Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Table 2 SUVmax of the detected lesions at each phase

	n	1 h	3 h	p value
Total	144	10.1 ± 10.6	16.7 ± 15.9	< 0.001
Local recurrence	14	6.5 ± 3.3	10.6 ± 5.4	< 0.001
Lymph node				
Pelvic	31	8.1 ± 8.0	13.3 ± 13.8	< 0.001
Distant	25	19.3 ± 17.1	29.7 ± 23.7	< 0.001
Bone	71	8.3 ± 7.5	15.2 ± 12.1	< 0.001
Other organ	3	10.2 ± 5.6	17.3 ± 9.4	0.125

Table 4 Comparison of patient-based detection rates between the treatment methods stratified by tumor location (3 h post-injection)

	RP ($n=35$) (%)	RT ($n=37$) (%)	p value*
Total	21 (60)	30 (81)	0.049
Local recurrence	4 (11)	13 (35)	0.018
Lymph node			
Pelvic	9 (26)	9 (24)	0.892
Distant	2 (6)	7 (19)	0.090
Bone	5 (14)	8 (22)	0.419
Other organ	2 (6)	1 (3)	0.523

RP radical prostatectomy, *RT* radiation therapy

*Chi-squared test